1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Quinones and nitrogen heterocyclic moieties have been recognized as important pharmacophores in the development of antitumor agents. This study aimed to establish whether there was any correlation between the in silico predicted parameters and the in vitro antiproliferative activity of a family of benzoindazolequinones (BIZQs), and to evaluate overexpressed proteins in human cancer cells as potential biomolecular targets of these compounds. For this purpose, this study was carried out using KATO-III and MCF-7 cell lines as in vitro models. Docking results showed that these BIZQs present better binding energies (ΔG bin ) values for cyclooxygenase-2 (COX-2) than for other cancer-related proteins. The predicted ∆G bin values of these BIZQs, classified in three series, positively correlated with IC 50 measured in both cell lines (KATO-III: 0.72, 0.41, and 0.90; MCF-7: 0.79, 0.55, and 0.87 for Series I, II, and III, respectively). The results also indicated that compounds 2a, 2c, 6g, and 6k are the most prominent BIZQs, because they showed better IC 50 and ∆G bin values than the other derivatives. In silico drug absorption, distribution, metabolism, and excretion (ADME) properties of the three series were also analyzed and showed that several BIZQs could be selected as potential candidates for cancer pre-clinical assays.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies.

          The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have been shown to play major roles not only in physiological but also in most pathological angiogenesis, such as cancer. VEGF belongs to the PDGF supergene family characterized by 8 conserved cysteines and functions as a homodimer structure. VEGF-A regulates angiogenesis and vascular permeability by activating 2 receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk1 in mice). On the other hand, VEGF-C/VEGF-D and their receptor, VEGFR-3 (Flt-4), mainly regulate lymphangiogenesis. The VEGF family includes other interesting variants, one of which is the virally encoded VEGF-E and another is specifically expressed in the venom of the habu snake (Trimeresurus flavoviridis). VEGFRs are distantly related to the PDGFR family; however, they are unique with respect to their structure and signaling system. Unlike members of the PDGFR family that strongly stimulate the PI3K-Akt pathway toward cell proliferation, VEGFR-2, the major signal transducer for angiogenesis, preferentially utilizes the PLCγ-PKC-MAPK pathway for signaling. The VEGF-VEGFR system is an important target for anti-angiogenic therapy in cancer and is also an attractive system for pro-angiogenic therapy in the treatment of neuronal degeneration and ischemic diseases.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prediction of drug solubility from structure.

            The aqueous solubility of a drug is an important factor affecting its bioavailability. Numerous computational methods have been developed for the prediction of aqueous solubility from a compound's structure. A review is provided of the methodology and quality of results for the most useful procedures including the model implemented in the QikProp program. Viable methods now exist for predictions with less than 1 log unit uncertainty, which is adequate for prescreening synthetic candidates or design of combinatorial libraries. Further progress with predictive methods would require an experimental database of highly accurate solubilities for a large, diverse collection of drug-like molecules.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships

              Non-steroidal anti-inflammatory drugs (NSAIDs) are the competitive inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs). Their use is associated with the side effects such as gastrointestinal and renal toxicity. The therapeutic anti-inflammatory action of NSAIDs is produced by the inhibition of COX-2, while the undesired side effects arise from inhibition of COX-1 activity. Thus, it was though that more selective COX-2 inhibitors would have reduced side effects. Based upon a number of selective COX-2 inhibitors (rofecoxib, celecoxib, valdecoxibetc.) were developed as safer NSAIDs with improved gastric safety profile. However, the recent market removal of some COXIBs such as rofecoxib due to its adverse cardiovascular side effects clearly encourages the researchers to explore and evaluate alternative templates with COX-2 inhibitory activity. Recognition of new avenues for selective COX-2 inhibitors in cancer chemotherapy and neurological diseases such as Parkinson and Alzheimer’s diseases still continues to attract investigations on the development of COX-2 inhibitors. This review highlights the various structural classes of selective COX-2 inhibitors with special emphasis on their structure-activity relationships.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Role: Academic Editor
                Journal
                Molecules
                Molecules
                molecules
                Molecules
                MDPI
                1420-3049
                18 June 2019
                June 2019
                : 24
                : 12
                : 2261
                Affiliations
                [1 ]Instituto de Química, Facultad de Ciencias, Pontificia Universidad Católica de Valparaíso, Valparaíso 2373223, Chile; alfonso.oliva@ 123456pucv.cl (A.O.); m.arismendi.m@ 123456gmail.com (M.A.-M.); leda.guzman@ 123456pucv.cl (L.G.); waldo.acevedo@ 123456pucv.cl (W.A.)
                [2 ]Centro de Bioinformática y Biología Integrativa, Facultad de Ciencias de la Vida, Universidad Nacional Andrés Bello, Santiago 8370146, Chile; daniel.aguayo@ 123456unab.cl
                [3 ]Laboratorio de Farmacología, Centro de Micro Bioinnovación, Facultad de Farmacia, Universidad de Valparaíso, Valparaíso 2360102, Chile; raul.vinet@ 123456uv.cl
                [4 ]Centro Regional de Estudios en Alimentos Saludables (CREAS), Valparaíso 2362696, Chile
                [5 ]Departamento de Ciencias Farmacéuticas-Química Farmacéutica, Facultad de Farmacia, CIETUS, IBSAL, Universidad de Salamanca, 37007 Salamanca, Spain; artsf@ 123456usal.es
                Author notes
                [* ]Correspondence: aurora.molinari@ 123456pucv.cl ; Tel.: +56-32-2274910
                Author information
                https://orcid.org/0000-0002-7607-8731
                https://orcid.org/0000-0002-8738-7476
                https://orcid.org/0000-0002-1182-0253
                https://orcid.org/0000-0002-4719-8910
                https://orcid.org/0000-0002-0578-0611
                Article
                molecules-24-02261
                10.3390/molecules24122261
                6630654
                31216654
                80cb1cc9-b256-488a-9865-12208687fcd3
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 22 May 2019
                : 15 June 2019
                Categories
                Article

                1h-benzo[f]indazole-4,9-diones,benzoindazolequinones,antiproliferative activity,cox-2 inhibitors,docking

                Comments

                Comment on this article